reference : Hopkins, P. E., & Halsey, R. F. (2023). Advanced accounting, 5e. page 118-120 a. AbbVie
Question:
reference : Hopkins, P. E., & Halsey, R. F. (2023). Advanced accounting, 5e. page 118-120
a. AbbVie describes its assignment of fair value as being “preliminary.” Briefly describe the procedure under GAAP for companies to use provisional amounts and the process by which those estimates can be adjusted.
b. Prepare the journal entry that AbbVie made for the acquisition of Allergan’s common stock.
c. Describe the process by which AbbVie determined the assignment of fair value to Goodwill in the amount of $27,044 million.
d. How much did AbbVie assign to identifiable intangible assets? Briefly describe the valuation approach used to determine the fair values of identifiable intangible assets. What significant assumptions are inherent in the estimation of intangible asset fair values?
e. For the three months ended June 30, 2020 AbbVie reported consolidated revenues of $10,425 million and a net loss of $738 million. For what period of time is Allergan’s performance included in AbbVie’s revenues and expenses for the three months ending June 30, 2020? How much did Allergan contribute to AbbVie’s revenues and net losses for the three months ended June 30, 2020? What would AbbVie’s revenues and net income be without the effect of Allergan?
f. How much in acquisition-related costs did AbbVie incur during the three months that ended June 30, 2020. How were these costs recognized in the financial statements?
g. Describe the entry that AbbVie makes in the consolidation process to remove the Equity Investment account from the parent-company balance sheet in preparation of the consolidated balance sheet.
Advanced Accounting
ISBN: 978-0538480284
11th edition
Authors: Paul M. Fischer, William J. Tayler, Rita H. Cheng